These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 30180286)

  • 21. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.
    Harper J; Lloyd C; Dimasi N; Toader D; Marwood R; Lewis L; Bannister D; Jovanovic J; Fleming R; D'Hooge F; Mao S; Marrero AM; Korade M; Strout P; Xu L; Chen C; Wetzel L; Breen S; van Vlerken-Ysla L; Jalla S; Rebelatto M; Zhong H; Hurt EM; Hinrichs MJ; Huang K; Howard PW; Tice DA; Hollingsworth RE; Herbst R; Kamal A
    Mol Cancer Ther; 2017 Aug; 16(8):1576-1587. PubMed ID: 28522587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural-source payloads used in the conjugated drugs architecture for cancer therapy: Recent advances and future directions.
    Li C; Shi K; Zhao S; Liu J; Zhai Q; Hou X; Xu J; Wang X; Liu J; Wu X; Fan W
    Pharmacol Res; 2024 Sep; 207():107341. PubMed ID: 39134188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Basics and Innovations in Antibody-Drug Conjugates].
    Manabe S
    Gan To Kagaku Ryoho; 2024 Jul; 51(7):681-685. PubMed ID: 39191680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?
    Jackson PJM; Kay S; Pysz I; Thurston DE
    Drug Discov Today Technol; 2018 Dec; 30():71-83. PubMed ID: 30553523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate.
    Puthenveetil S; He H; Loganzo F; Musto S; Teske J; Green M; Tan X; Hosselet C; Lucas J; Tumey LN; Sapra P; Subramanyam C; O'Donnell CJ; Graziani EI
    PLoS One; 2017; 12(5):e0178452. PubMed ID: 28558059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates.
    Boghaert ER; Cox MC; Vaidya KS
    Cancer Res; 2022 May; 82(10):1858-1869. PubMed ID: 35298624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
    White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
    MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
    Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
    Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned.
    López de Sá A; Díaz-Tejeiro C; Poyatos-Racionero E; Nieto-Jiménez C; Paniagua-Herranz L; Sanvicente A; Calvo E; Pérez-Segura P; Moreno V; Moris F; Ocana A
    J Hematol Oncol; 2023 Dec; 16(1):118. PubMed ID: 38087293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates.
    Gromek SM; Balunas MJ
    Curr Top Med Chem; 2015; 14(24):2822-34. PubMed ID: 25487009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amanitins and their development as a payload for antibody-drug conjugates.
    Pahl A; Lutz C; Hechler T
    Drug Discov Today Technol; 2018 Dec; 30():85-89. PubMed ID: 30553524
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Payload diversification: a key step in the development of antibody-drug conjugates.
    Conilh L; Sadilkova L; Viricel W; Dumontet C
    J Hematol Oncol; 2023 Jan; 16(1):3. PubMed ID: 36650546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel antibody-KSP inhibitor conjugate improves KSP inhibitor efficacy in vitro and in vivo.
    Li Y; Wang Z; Dong Y; Yu X; Lu J; Jin N; Shang C; Li X; Fan S
    Biomaterials; 2023 Oct; 301():122258. PubMed ID: 37523792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
    Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
    Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
    Chen H; Lin Z; Arnst KE; Miller DD; Li W
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy.
    Chowdari NS; Pan C; Rao C; Langley DR; Sivaprakasam P; Sufi B; Derwin D; Wang Y; Kwok E; Passmore D; Rangan VS; Deshpande S; Cardarelli P; Vite G; Gangwar S
    Bioorg Med Chem Lett; 2019 Feb; 29(3):466-470. PubMed ID: 30579797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
    Tsuchikama K
    Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.